Accurate detection of intracranial extension of jugulotympanic paraganglioma by [18F]FDOPA-PET/CT comparing to MRI

Zahra Jamshidi Araghi1 · Shaghayegh Ranjbar1 · Michael Paar2 · Christian Pirich1 · Mohsen Beheshti1

Received: 17 June 2021 / Accepted: 3 July 2021 / Published online: 11 August 2021
© The Author(s) 2021

Jugulotympanic paraganglioma (JTP) is a rare, slow-growing, and usually benign tumor in the jugular foramen [1, 2]. Magnetic resonance imaging (MRI) is used as modality of choice for assessment of JTP [3, 4]. Positron emission tomography–computed tomography (PET/CT) using specific radiotracers (e.g., 68 Ga-DOTA-derivatives) have been performed for localization of multifocal JTP or sites of metastases in malignant tumors [5, 6]. However, the impact of PET/CT using [18F]fluorodihydroxyphenylalanin ([18F]FDOPA), as a specific radiotracer for neuroendocrine tumors (NET), has been less presented in the literature. This particular case presents the superior value of [18F]FDOPA-PET/CT comparing to MRI for depiction of the entire tumor extent in a 53-year-old woman presented with progressive symptoms of vertigo and recurrent tinnitus on the left side for 6 months. Brain MRI reported an osteodestructive mass in the area of the left jugular foramen, extending caudally along the cervical nerve sheath up to the level of hyoid (e–h, arrows).

[18F]FDOPA-PET/CT has more accurately defined the intracranial extension of the JPT showing a diffuse, intense tracer uptake in the left jugular foramen, extending to the ipsilateral sigmoid sinus, with tumor growth along the left cerebellar hemisphere up to the lateral aspect of cerebellar...
a. [18F]FDOPA PET: MIP (Maximum Intensity Projection) anterior view shows intensive tracer uptake along the left cervical and intracranial regions. 

b. [18F]FDOPA PET: MIP left lateral c–d. [18F] FDOPA PET (upper row) and fused PET/CT axial images (lower row) show intensive tracer uptake in the area of the left jugular foramen (b–c, black arrow) with cranial extension to the ipsilateral sigmoid sinus, and condylar emissary vein (b–c, red arrow), and an intracranial extension along the left cerebellar hemisphere to the lateral aspect of cerebellar tentorium (b–d, arrowhead). In the caudal dimension, the tumoral tissue shows intensive tracer uptake along the cervical vascular nerve sheath to the level of the hyoid bone. In addition, a small tumoral extension with faint uptake is also seen in the splenius capitis muscle region (b–c, blue arrow).

e–h. Magnetic Resonance Imaging (MRI) axial T1 fat suppression with intravenous Gadolinium (e–g), axial T2 TSE (h) demonstrating large tumour expansion centred at the jugular foramen with local bony destruction. Contrast enhancement with typical salt and pepper-appearance with multiple internal flow voids are best seen in T2. Tumoral extension is evident in the sigmoid sinus (f, arrow), the condylar emissary vein via the condylar canal (g, yellow arrow) as well extra cranially along the internal jugular vein with encasement of the internal carotid artery (g–h, white arrow).
tentorium and caudally along the cervical vascular nerve sheath to the level of the hyoid bone (SUV max. 26.3) (a–d. arrows). JPT was approved by histopathology. A physiologic intense [18F]FDOPA-PET/CT uptake was also seen in the gallbladder as excretory organ (a and b, green arrow).

The present case emphasizes again on the added value of functional PET imaging using specific radiotracers for the accurate assessment of JPTs, especially when performing in a hybrid PET/MRI setting.

Funding Open access funding provided by Paracelsus Medical University.

Declarations

Ethics approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent Informed consent was obtained from the individual participant included in the study for performing the [18F]FDOPA-PET/CT examination.

Competing interests The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Lenders JW, Duh Q-Y, Eisenhofer G, Gimenez-Roqueplo A-P, Grebe SK, Murad MH, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. 2014;99:1915–42.
2. Papathomas TG, Gaal J, Corssmit E, Oudijk L, Korpershoek E, Heimdal K, et al. Non-pheochromocytoma (PCC)/paraganglioma (PGL) tumors in patients with succinate dehydrogenase-related PCC-PGL syndromes: a clinicopathological and molecular analysis. 2014;170:1–12.
3. Wippold FJ 2nd. Head and neck imaging: the role of CT and MRI. J Magn Reson Imaging. 2007;25:453–65. https://doi.org/10.1002/jmri.20838.
4. Thelen J, Bhatt AA. Multimodality imaging of paragangliomas of the head and neck. Insights Imaging. 2019;10:29. https://doi.org/10.1186/s13244-019-0701-2.
5. Taïeb D, Hicks RJ, Hindié E, Guillet BA, Avram A, Ghedini P, et al. European association of nuclear medicine practice guideline/society of nuclear medicine and molecular imaging procedure standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. 2019;46:2112–37.
6. Taïeb D, Neumann H, Rubello D, Al-Nahhas A, Guillet B, Hindié E. Modern nuclear imaging for paragangliomas: beyond SPECT. J Nucl Med. 2012;53:264–74. https://doi.org/10.2967/jnumed.111.098152.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.